乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化

肝脏 ›› 2020, Vol. 25 ›› Issue (2): 123-127.

乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化

孔媛媛, 魏巍, 单姗, 马红, 欧晓娟, 徐小元, 段钟平, 侯金林, 魏来, 尤红, 贾继东, 中国消除乙肝临床科研平台(CR-HepB)研究组

100050 首都医科大学附属北京友谊医院临床流行病学与循证医学中心国家消化系统疾病临床医学研究中心(孔媛媛,魏巍),肝病中心(单姗,马红,欧晓娟,尤红,贾继东);北京大学第一医院感染疾病科(徐小元);首都医科大学附属北京佑安医院肝病科(段钟平);北京清华长庚医院肝胆胰内科(魏来);南方医科大学南方医院感染内科(侯金林)

收稿日期:2019-11-14 出版日期:2020-02-29 发布日期:2020-03-26
通讯作者: 贾继东,Email:jia_jd@ccmu.edu.cn
基金资助:
国家科技重大专项课题“消化系统炎性疾病新药临床评价技术平台建设” (2018ZX09201016);北京市科学技术委员会医药协同科技创新研究专项“肝病创新药物早期临床试验关键技术规范研究” (Z191100007619037);北京市医院管理局消化内科学科协同发展中心消化专项协作创新课题“消化系统疾病临床研究区域数据协调与质促协同平台建设” (XXX0104)

Clinical profiles and treatment patterns of patients with HBV-related liver cirrhosis

KONG Yuan-yuan¹, WEI Wei¹, SHAN Shan², MA Hong², OU Xiao-juan², XU Xiao-yuan³, DUAN Zhong-ping⁴, HOU Jin-lin⁵, WEI Lai⁶, YOU Hong², JIA Ji-dong², CR-HepB Group

1. Clinical Epidemiology and EBM Unit, Beijing Friendship Hospital, Capital Medical University, National Clinical Research Center for Digestive Diseases, Beijing 100050, China;
2. Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China;
3. Peking University First Hospital, Beijing, 100034, China;
4. Beijing YouAn Hospital, Capital Medical University, Beijing, 100069, China;
5. Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China;
6. Beijing Tsinghua Changguang Hospital, Beijing 102218, China

Received:2019-11-14 Online:2020-02-29 Published:2020-03-26
Contact: JIA Ji-dong, E-mail: jia_jd@ccmu.edu.cn

摘要/Abstract

摘要： 目的了解我国乙型肝炎肝硬化患者的临床特征和治疗模式及变化趋势。方法从CR-HepB系统提取历年相关数据,描述患者的一般临床资料、病毒学、血液学、生化、治疗用药信息,并分析其变化趋势。结果研究共纳入5 263例乙型肝炎肝硬化患者,其中代偿期患者2 013例(38.2%),失代偿期患者2 752例(52.3%),未确定代偿或失代偿期患者498例(9.5%)。自2010年至2019年,诊断为乙型肝炎肝硬化时年龄≥50岁者由45.6%升至57.9%,HBeAg阳性率由47.4%降至35.8%,一线抗病毒药物(恩替卡韦和替诺福韦酯)选用比例由41.9%升至92.8%。结论我国乙型肝炎肝硬化患者的诊断年龄逐渐增高、HBeAg阳性率下降,一线抗病毒药物使用比例明显提高。

关键词: 慢性乙型肝炎, 肝硬化, 抗病毒治疗, 真实世界研究

Abstract: Objective To analyze the clinical profiles and treatment patterns of patients with hepatitis B virus (HBV)-related cirrhosis in real-world clinical setting in China. Methods The demographic, clinical and treatment data were analyzed from enrolled patients in China Registry of Hepatitis B. Results A total of 5263 patients with HBV-related liver cirrhosis were included in the study, including 2013 (38.2%) patients with compensated status, 2752 patients (52.3%) with decompensated status and 498 patients (9.5%) unspecified. From 2010 to 2019, the proportion of patients ≥ 50 years old in those diagnosed with cirrhosis increased from 45.6% to 57.9%, the hepatitis B envelope antigen (HBeAg) positive rate decreased from 47.4% to 35.8%, and the use of the first-line antiviral drugs (entecavir or tenofovir) increased from 41.9% to 92.8%. Conclusion The real-world study demonstrated that the age of patients with diagnosis of cirrhosis gradually increased, the HBeAg positive rate gradually decreased, and the use of first-line antiviral drugs dramatically increased.

Key words: Chronic hepatitis B, Liver cirrhosis, Antiviral therapy, Real-world study

孔媛媛, 魏巍, 单姗, 马红, 欧晓娟, 徐小元, 段钟平, 侯金林, 魏来, 尤红, 贾继东, 中国消除乙肝临床科研平台(CR-HepB)研究组. 乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化[J]. 肝脏, 2020, 25(2): 123-127.

KONG Yuan-yuan, WEI Wei, SHAN Shan, MA Hong, OU Xiao-juan, XU Xiao-yuan, DUAN Zhong-ping, HOU Jin-lin, WEI Lai, YOU Hong, JIA Ji-dong, CR-HepB Group. Clinical profiles and treatment patterns of patients with HBV-related liver cirrhosis[J]. Chinese Hepatolgy, 2020, 25(2): 123-127.

参考文献

[1] Wang X, Lin SX, Tao J, et al. Study of liver cirrhosis over ten consecutive years in South- ern China. World J Gastroenterol,2014,20:13546-13555.
[2] Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol,2019, 70:151-71.
[3] Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int,2012,32:1333-41.
[4] Wu X, Zhou J, Xie W, et al. Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study. Infect Drug Resist,2019,12:745-757.
[5] Li M, Kong YY, Wu SS, et al. Impact of reimbursement program on liver-related mortality in patients with chronic hepatitis B in Beijing, China. J Dig Dis,2019,20:467-475.
[6] 中华医学会肝病学分会、感染病分会. 慢性乙型肝炎防治指南. 中华肝脏杂志,2015, 23:888-900.
[7] Shan S, Wei W, Kong YY, et al. China Registry of Hepatitis B (CR-HepB): protocol and implementation of a nationwide hospital-based registry of hepatitis B. Scand J Public Health. 2018 :1403494818772188. doi: 10.1177/1403494818772188. [Epub ahead of print]
[8] Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med,2016,375:767-77
[9] 中华医学会肝病学分会. 肝硬化诊治指南. 临床肝胆病杂志,2019,35:2408-2425.
[10] Cui F, Shen L, Li L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China. Emerg Infect Dis,2017,23:765-772.
[11] Liu J, Liang W, Jing W, et al. Countdown to 2030: eliminating hepatitis B disease, China. Bull World Health Organ,2019,97:230-238.
[12] Likhitsup A, Lok AS. Understanding the natural history of hepatitis B virus infection and the new definitions of cure and the endpoints of clinical trials. Clin Liver Dis,2019,23:401-416.
[13] You H, Kong YY, Hou JL, et al. Female gender lost protective effect against disease progression in elderly patients with chronic hepatitis B. Sci Rep,2016,6:37498.
[14] Ruggieri A, Gagliardi MC, Anticoli S. Sex-Dependent outcome of hepatitis B and C viruses infections: synergy of sex hormones and immune responses? Front Immunol,2018,9:2302.
[15] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol,2018,3:383-403.
[16] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology,2018,67:1560-1599.
[17] European Association for the Study of the Liver. EASL2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol,2017,67:370-398.
[18] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int,2016,10:1-98.
[19] Jia J, Tang H, Ning Q, Jiang J, et al; EVOLVE Study Group. Real-world evidence for nucleoside/nucleotide analogues in a 5-year multicentre study of antiviral-naive chronic hepatitis B patients in China: 52-week results. Antivir Ther,2018,23:201-209.
[20] Wei L, Jia JD, Weng XH, et al. Treating chronic hepatitis B virus: Chinese physicians' awareness of the 2010 guidelines. World J Hepatol,2016,8:762-9.
[21] Choi J, Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol,2019,5:30-36.
[22] Kim SU, Seo YS, Lee HA, et al. A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in the Republic of Korea. J Hepatol,2019,71:456-464.